According to EurekaAlert, Novo Biosciences Inc., a spinoff of the MDI Biological Laboratory in Bar Harbor, Maine, has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack. “We believe MSI-1436 has enormous potential,” said Kevin Strange, Ph.D., CEO of Novo Biosciences and president of the MDI Biological Laboratory. “No drug now exists to treat heart attack. Heart disease is the the world’s leading killer. In order to advance MSI-1436 into clinical trials, we need to first test its effectiveness in a large animal model. We are deeply grateful to the National Heart, Lung, and Blood Institute for making this possible.” Read more
Related Posts
Husson creates institute for leadership and workforce development
Husson University in Bangor has launched an institute dedicated to strategic leadership and workforce development training and education. Founded by the...
Swiss optics supplier acquires Portland-based Gray Optics
The acquisition of Gray Optics in Portland by a Swiss photonics firm expands the latter’s presence in the U.S. while allowing...
ElleVet Sciences, the Leading Pet CBD+CBDA Brand in the United States, Expands into Europe
PORTLAND, Maine, Feb. 15, 2023 /PRNewswire/ — ElleVet Sciences announced today that it is expanding its global reach with its new European Headquarters...